Peer-reviewed veterinary case report
Survival after surgery and doxorubicin for dog spleen cancer
By Matsuyama, Arata et al.·Published in Journal of the American Animal Hospital Association·2017·From the Department of Biomedical Sciences (A.M., Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
- Species:
- dog
Plain-English summary
A group of 33 dogs diagnosed with splenic hemangiosarcoma (a type of cancer affecting the spleen) underwent surgery followed by a chemotherapy drug called doxorubicin. Some of these dogs also received a second medication, low-dose metronomic cyclophosphamide, to see if it would help them live longer. Unfortunately, the study found that adding this second drug did not significantly improve how long the dogs lived or how long they were free from disease progression compared to those who only received doxorubicin. Overall, the average survival time was about 133 days after starting treatment.
People also search for: dog hemangiosarcoma treatment · doxorubicin for dogs cancer · canine cancer survival rates
Abstract
This retrospective study investigated the outcome of 33 dogs with splenic hemangiosarcoma treated with surgery followed by adjuvant dose-intensified doxorubicin (DOX) with or without low-dose metronomic cyclophosphamide (LDM-C) maintenance therapy. Among the 33 dogs, 18 dogs received LDM-C. Clinical stage was available for all dogs (5 stage I, 18 stage II, and 10 stage III). Nine dogs had macroscopic, and 24 dogs had microscopic disease at the start of DOX treatment. Median progression-free survival (PFS) and overall survival were 125 and 133 days, respectively. Clinical stage and tumor burden (microscopic versus macroscopic) at the start of chemotherapy was prognostic for PFS. No significant difference was observed in PFS or overall survival for the addition of LDM-C after a completed DOX protocol (P = .563 and P = .148, respectively). Based on the results of this retrospective study, the addition of LDM-C therapy as a maintenance regimen following a completed protocol of DOX adjuvant treatment of canine hemangiosarcoma may not improve outcome.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28892429/